抗肿瘤抗生素抗体靶向药物研究新进展  

Recent progresses on antibody-targeted conjugates of antitumor antibiotics

作　　者：尚利娜[1] 洪明岳[1] 

机构地区：[1]南京明基医院药剂部,南京医科大学附属医院

出　　处：《中国临床药理学与治疗学》2014年第9期1075-1080,共6页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：新近研究发现,卡里奇霉素、力达霉素等抗肿瘤抗生素对某些靶点显示高度活性,对癌细胞具有极强的杀伤作用,可以作为高效"弹头"药物,用于构建抗体靶向药物,包括化学免疫偶联物和融合蛋白。抗体靶向药物由于体内分布的特异性及作用的专一性,具有强大的抗肿瘤优势。本文主要对几类抗肿瘤抗生素抗体靶向药物的构建及作用特点等进行综述,并初步展望其未来研究方向。Recent studies have reported that some antibiotics such as calicheamicin and lidamycin display potent cytotoxicity respectively to variousmolecular targets, so they can be used as potent ＂warhead＂ agent to constitute antibodytargeted conjugates including immunoconjugates and fusion proteins. Antibody-targeted drugs exert a powerful antitumor potency because of its specific distribution and function in vivo. This paper mainly reviews on the construction and effect characteristics of antibody-targeted conjugates of antitumor antibiotics and provide a preliminary outlook for its future research direction.

关 键 词：抗肿瘤抗生素 抗体靶向药物 免疫偶合物 强化融合蛋白 

分 类 号：R963[医药卫生—微生物与生化药学]